Viruses as key regulators of angiogenesis

Reviews in Medical Virology

Volumn 21, Issue 3, 2011, Pages 181-200

  Vrancken, Kristof ^a   Vervaeke, Peter ^a   Balzarini, Jan ^a   Liekens, Sandra ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Chemokines; Endothelial cells; Growth factors; Neovascularization; Oncogenes; Proteolytic enzymes

Indexed keywords

ANGIOGENESIS MODULATOR; CHEMOKINE; CYTOKINE; GROWTH FACTOR; MATRIX METALLOPROTEINASE; TRANSACTIVATOR PROTEIN; VASCULOTROPIN; VIRUS PROTEIN;

ANGIOGENESIS; CARCINOGENESIS; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; PROTEIN DOMAIN; REVIEW; VIRUS; VIRUS GENE; WART VIRUS;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VIRAL PROTEINS; VIRAL TROPISM; VIRULENCE FACTORS; VIRUSES;

EID: 79955458611     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.688     Document Type: Review

References (167)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
2. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer and Metastasis Reviews 2007; 26: 281-290.
3. Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovascular Research 2010; 86: 236-242.
4. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Seminars in Cancer Biology 2010; 20: 161-168.
5. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochemical Pharmacology 2001; 61: 253-270.
6. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature Reviews Drug Discovery 2007; 6: 273-286.
7. Ferrara N. Vascular endothelial growth factor. Arteriosclerosis, Thrombosis, and Vascular Biology 2009; 29: 789-791.
8. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
9. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178.
10. Keeley EC, Mehrad B, Strieter RM. CXC chemokines in cancer angiogenesis and metastases. Advances in Cancer Research 2010; 106: 91-111.
11. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006; 72: 1605-1621.
12. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. The Journal of Biological Chemistry 1996; 271: 736-741.
13. Yao JS, Zhai W, Young WL, Yang GY. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochemical and Biophysical Research Communications 2006; 342: 1396-1404.
14. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386.
15. Tello-Montoliu A, Patel JV, Lip GY. Angiogenin: a review of the pathophysiology and potential clinical applications. Journal of Thrombosis and Haemostasis 2006; 4: 1864-1874.
16. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Medicinal Research Reviews 2009; 29: 903-953.
17. Contois L, Akalu A, Brooks PC. Integrins as "functional hubs" in the regulation of pathological angiogenesis. Seminars in Cancer Biology 2009; 19: 318-328.
18. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Developmental Cell 2009; 16: 209-221.
19. Martin D, Gutkind JS. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 2008; 27 Suppl 2: S31-S42.
20. Young LS, Rickinson AB. Epstein-Barr virus: 40years on. Nature Reviews. Cancer 2004; 4: 757-768.
21. Yoshizaki T, Horikawa T, Qing-Chun R, et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clinical Cancer Research 2001; 7: 1946-1951.
22. Tsuji A, Wakisaka N, Kondo S, Murono S, Furukawa M, Yoshizaki T. Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clinical Cancer Research 2008; 14: 5368-5375.
23. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 6905-6910.
24. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000; 89: 715-723.
25. Chen CC, Chen LC, Liang Y, Tsang NM, Chang YS. Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways. Cellular Signalling 2010; 22: 1132-1142.
26. Paydas S, Ergin M, Erdogan S, Seydaoglu G. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leukemia Research 2008; 32: 1424-1430.
27. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-399.
28. Kondo S, Seo SY, Yoshizaki T, et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Research 2006; 66: 9870-9877.
29. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Molecular and Cellular Biology 2004; 24: 5223-5234.
30. Wakisaka N, Murono S, Yoshizaki T, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Research 2002; 62: 6337-6344.
31. Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 3621-3626.
32. Lu J, Chua HH, Chen SY, Chen JY, Tsai CH. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Research 2003; 63: 256-262.
33. Stevenson D, Charalambous C, Wilson JB. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Research 2005; 65: 8826-8835.
34. O'Neil JD, Owen TJ, Wood VH, et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. The Journal of General Virology 2008; 89: 2833-2842.
35. Sakakibara S, Tosato G. Regulation of angiogenesis in malignancies associated with Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus. Future Microbiology 2009; 4: 903-917.
36. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nature Reviews. Cancer 2010; 10: 707-719.
37. Boshoff C, Schulz TF, Kennedy MM, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Medicine 1995; 1: 1274-1278.
38. Chiou CJ, Poole LJ, Kim PS, et al. Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus. Journal of Virology 2002; 76: 3421-3439.
39. Naranatt PP, Krishnan HH, Svojanovsky SR, Bloomer C, Mathur S, Chandran B. Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Research 2004; 64: 72-84.
40. Poole LJ, Yu Y, Kim PS, Zheng QZ, Pevsner J, Hayward GS. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. Journal of Virology 2002; 76: 3395-3420.
41. Sivakumar R, Sharma-Walia N, Raghu H, et al. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. Journal of Virology 2008; 82: 1759-1776.
42. Sadagopan S, Sharma-Walia N, Veettil MV, et al. Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. Journal of Virology 2009; 83: 3342-3364.
43. Ye FC, Blackbourn DJ, Mengel M, et al. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. Journal of Virology 2007; 81: 3980-3991.
44. Sharma-Walia N, Paul AG, Bottero V, et al. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathogens 2010; 6: e1000777.
45. Lane BR, Liu J, Bock PJ, et al. Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma. Journal of Virology 2002; 76: 11570-11583.
46. Qian LW, Xie J, Ye F, Gao SJ. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. Journal of Virology 2007; 81: 7001-7010.
47. Carroll PA, Kenerson HL, Yeung RS, Lagunoff M. Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. Journal of Virology 2006; 80: 10802-10812.
48. Qian LW, Greene W, Ye F, Gao SJ. Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin. Journal of Virology 2008; 82: 11902-11912.
49. Watanabe T, Sugaya M, Atkins AM, et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. Journal of Virology 2003; 77: 6188-6196.
50. Cai Q, Murakami M, Si H, Robertson ES. A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. Journal of Virology 2007; 81: 10413-10423.
51. Sakakibara S, Pise-Masison CA, Brady JN, Tosato G. Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells. Journal of Virology 2009; 83: 2140-2153.
52. Samols MA, Skalsky RL, Maldonado AM, et al. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathogens 2007; 3: e65.
53. Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Medicine 2010; 16: 909-914.
54. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278: 290-294.
55. Stine JT, Wood C, Hill M, et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000; 95: 1151-1157.
56. Cherqui S, Kingdon KM, Thorpe C, Kurian SM, Salomon DR. Lentiviral gene delivery of vMIP-II to transplanted endothelial cells and endothelial progenitors is proangiogenic in vivo. Molecular Therapy 2007; 15: 1264-1272.
57. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999; 93: 4034-4043.
58. Vart RJ, Nikitenko LL, Lagos D, et al. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Research 2007; 67: 4042-4051.
59. Shin YC, Joo CH, Gack MU, Lee HR, Jung JU. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. Cancer Research 2008; 68: 1751-1759.
60. Wang L, Wakisaka N, Tomlinson CC, et al. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Research 2004; 64: 2774-2781.
61. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997; 385: 347-350.
62. Bais C, Van Geelen A, Eroles P, et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 2003; 3: 131-143.
63. Sodhi A, Montaner S, Patel V, et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 4821-4826.
64. Sodhi A, Chaisuparat R, Hu J, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10: 133-143.
65. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Research 2000; 60: 4873-4880.
66. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 2005; 24: 2067-2075.
67. Pati S, Cavrois M, Guo HG, et al. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. Journal of Virology 2001; 75: 8660-8673.
68. Polson AG, Wang D, DeRisi J, Ganem D. Modulation of host gene expression by the constitutively active G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus. Cancer Research 2002; 62: 4525-4530.
69. Yen-Moore A, Hudnall SD, Rady PL, et al. Differential expression of the HHV-8 vGCR cellular homolog gene in AIDS-associated and classic Kaposi's sarcoma: potential role of HIV-1 Tat. Virology 2000; 267: 247-251.
70. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Reviews in Medical Virology 2009; 19: 97-113.
71. Nair P, Gangadevi T, Jayaprakash P, Nair M, Nair M, Pillai M. Increased angiogenesis in the uterine cervix associated with human papillomavirus infection. Pathology, Research and Practice 1999; 195: 163-169.
72. Mullerat J, Wong Te Fong LF, Davies SE, Winslet MC, Perrett CW. Angiogenesis in anal warts, anal intraepithelial neoplasia and anal squamous cell carcinoma. Colorectal Disease 2003; 5: 353-357.
73. Harada K, Lu S, Chisholm DM, Syrjanen S, Schor AM. Angiogenesis and vasodilation in skin warts. Association with HPV infection. Anticancer Res 2000; 20: 4519-4523.
74. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000; 19: 4611-4620.
75. Bequet-Romero M, Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochemical and Biophysical Research Communications 2000; 277: 55-61.
76. Xi L, Wang S, Wang C, et al. The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts. Oncology Reports 2009; 21: 25-31.
77. Chen W, Li F, Mead L, et al. Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology 2007; 367: 168-174.
78. Toussaint-Smith E, Donner DB, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 2004; 23: 2988-2995.
79. Kim SH, Juhnn YS, Kang S, et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1, 2 and PI3K/Akt. Cellular and Molecular Life Sciences 2006; 63: 930-938.
80. Tang X, Zhang Q, Nishitani J, Brown J, Shi S, Le AD. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clinical Cancer Research 2007; 13: 2568-2576.
81. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
82. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor c. Genes & Development 2000; 14: 34-44.
83. Smola-Hess S, Pahne J, Mauch C, Zigrino P, Smola H, Pfister HJ. Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. The Journal of General Virology 2005; 86: 1291-1296.
84. Le BH, Lachgar A, D'Anna R, et al. Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein. Biomedicine & Pharmacotherapy 1999; 53: 323-328.
85. D'Anna R, Le BH, Alessandri G, et al. Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoprotein. Journal of the National Cancer Institute 2001; 93: 1843-1851.
86. Fule T, Mathe M, Suba Z, et al. The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. Virology 2006; 348: 289-296.
87. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324.
88. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. Journal of Hepatology 2004; 41: 864-880.
89. Lee SW, Lee YM, Bae SK, Murakami S, Yun Y, Kim KW. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochemical and Biophysical Research Communications 2000; 268: 456-461.
90. Yun C, Lee JH, Wang JH, et al. Expression of hepatitis B virus X (HBx) gene is up-regulated by adriamycin at the post-transcriptional level. Biochemical and Biophysical Research Communications 2002; 296: 1157-1163.
91. Moon EJ, Jeong CH, Jeong JW, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. The FASEB Journal 2004; 18: 382-384.
92. Yoo YG, Oh SH, Park ES, et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. The Journal of Biological Chemistry 2003; 278: 39076-39084.
93. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Archives of Pathology & Laboratory Medicine 2000; 124: 1061-1065.
94. Dai CX, Gao Q, Qiu SJ, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009; 9: 418.
95. Sanz-Cameno P, Martin-Vilchez S, Lara-Pezzi E, et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. The American Journal of Pathology 2006; 169: 1215-1222.
96. Chen ZB, Shen SQ, Ding YM, et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Medical Oncology 2009; 26: 365-371.
97. Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. Journal of Clinical Investigation 2002; 110: 1831-1838.
98. Ou DP, Tao YM, Tang FQ, Yang LY. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. International Journal of Cancer 2007; 120: 1208-1214.
99. Yu FL, Liu HJ, Lee JW, Liao MH, Shih WL. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. Journal of Hepatology 2005; 42: 520-527.
100. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. The FASEB Journal 2004; 18: 1123-1125.
101. Zhang J, Niu D, Sui J, Ching CB, Chen WN. Protein profile in hepatitis B virus replicating rat primary hepatocytes and HepG2 cells by iTRAQ-coupled 2-D LC-MS/MS analysis: insights on liver angiogenesis. Proteomics 2009; 9: 2836-2845.
102. Salcedo X, Medina J, Sanz-Cameno P, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42: 696-701.
103. Gabriel A, Kukla M, Wilk M, Liszka L, Petelenz M, Musialik J. Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage. Pathology, Research and Practice 2009; 205: 758-764.
104. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. Journal of Clinical Pathology 2004; 57: 867-871.
105. Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. Journal of Virology 2007; 81: 10249-10257.
106. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 9599-9604.
107. Hassan M, Selimovic D, Ghozlan H, Abdel-kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009; 49: 1469-1482.
108. Li Y, Chen J, Wu C, Wang L, Lu M, Chen X. Hepatitis B virus/hepatitis C virus upregulate angiopoietin-2 expression through mitogen-activated protein kinase pathway. Hepatology Research 2010; 40: 1022-1033.
109. Shin JY, Hur W, Wang JS, et al. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Experimental & Molecular Medicine 2005; 37: 138-145.
110. Mazzocca A, Sciammetta SC, Carloni V, et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. The Journal of Biological Chemistry 2005; 280: 11329-11339.
111. Nunez O, Fernandez-Martinez A, Majano PL, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004; 53: 1665-1672.
112. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews. Cancer 2007; 7: 270-280.
113. Bazarbachi A, Abou MR, Gessain A, et al. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Research 2004; 64: 2039-2046.
114. Hayashibara T, Yamada Y, Miyanishi T, et al. Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion. Clinical Cancer Research 2001; 7: 2719-2726.
115. El-Sabban ME, Merhi RA, Haidar HA, et al. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood 2002; 99: 3383-3389.
116. Kchour G, Makhoul NJ, Mahmoudi M et al. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leukaemia & Lymphoma 2007; 48: 330-336.
117. Kchour G, Tarhini M, Sharifi N et al. Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma. Leukaemia & Lymphoma 2008; 49: 265-270.
118. Watters KM, Dean J, Gautier V, Hall WW, Sheehy N. Tax 1-independent induction of vascular endothelial growth factor in adult T-cell leukemia caused by human T-cell leukemia virus type 1. Journal of Virology 2010; 84: 5222-5228.
119. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335: 606-611.
120. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229: 69-73.
121. Barillari G, Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clinical Microbiology Reviews 2002; 15: 310-326.
122. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002; 5: 141-151.
123. Albini A, Benelli R, Presta M, et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996; 12: 289-297.
124. Barillari G, Sgadari C, Fiorelli V, et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 1999; 94: 663-672.
125. Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nature Medicine 1996; 2: 1371-1375.
126. Toschi E, Bacigalupo I, Strippoli R, et al. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Molecular Biology of the Cell 2006; 17: 1985-1994.
127. Urbinati C, Mitola S, Tanghetti E, et al. Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 2005; 25: 2315-2320.
128. Boykins RA, Mahieux R, Shankavaram UT, et al. Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. Journal of Immunology 1999; 163: 15-20.
129. Benelli R, Barbero A, Ferrini S, et al. Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis. The Journal of Infectious Diseases 2000; 182: 1643-1651.
130. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 4838-4842.
131. Fiorelli V, Barillari G, Toschi E, et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. Journal of Immunology 1999; 162: 1165-1170.
132. Barillari G, Sgadari C, Palladino C, et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. Journal of Immunology 1999; 163: 1929-1935.
133. Corallini A, Altavilla G, Pozzi L, et al. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Research 1993; 53: 5569-5575.
134. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674-680.
135. Caposio P, Orloff SL, Streblow DN. The role of cytomegalovirus in angiogenesis. Virus Research 1 October 2010 [Epub ahead of print].
136. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Research 29 October 2010 [Epub ahead of print].
137. Schuessler A, Sampaio KL, Scrivano L, Sinzger C. Mutational mapping of UL130 of human cytomegalovirus defines peptide motifs within the C-terminal third as essential for endothelial cell infection. Journal of Virology 2010; 84: 9019-9026.
138. Bentz GL, Yurochko AD. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 5531-5536.
139. Dumortier J, Streblow DN, Moses AV, et al. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. Journal of Virology 2008; 82: 6524-6535.
140. Botto S, Streblow DN, Defilippis V, et al. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood 2011; 117(1): 352-361.
141. Streblow DN, Kreklywich CN, Andoh T, et al. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. American Journal of Transplantation 2008; 8: 277-287.
142. Maussang D, Verzijl D, van Walsum M, et al. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 13068-13073.
143. Maussang D, Langemeijer E, Fitzsimons CP, et al. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Research 2009; 69: 2861-2869.
144. Bongers G, Maussang D, Muniz LR et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. Journal of Clinical Investigation 2010; 120: 3969-3978.
145. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clinical Microbiology Reviews 2005; 18: 217-245.
146. Wu CA, Shanley JD. Chronic infection of human umbilical vein endothelial cells by human herpesvirus-6. The Journal of General Virology 1998; 79 (Pt 5): 1247-1256.
147. Rotola A, Di Luca D, Cassai E, et al. Human herpesvirus 6 infects and replicates in aortic endothelium. Journal of Clinical Microbiology 2000; 38: 3135-3136.
148. Caruso A, Caselli E, Fiorentini S, et al. U94 of human herpesvirus 6 inhibits in vitro angiogenesis and lymphangiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 20446-20451.
149. Caruso A, Rotola A, Comar M, et al. HHV-6 infects human aortic and heart microvascular endothelial cells, increasing their ability to secrete proinflammatory chemokines. Journal of Medical Virology 2002; 67: 528-533.
150. Kaye S, Choudhary A. Herpes simplex keratitis. Progress in Retinal and Eye Research 2006; 25: 355-380.
151. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. Journal of Virology 2001; 75: 9828-9835.
152. Biswas PS, Banerjee K, Kinchington PR, Rouse BT. Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Experimental Eye Research 2006; 82: 46-54.
153. Lee S, Zheng M, Kim B, Rouse BT. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. Journal of Clinical Investigation 2002; 110: 1105-1111.
154. Yang YN, Bauer D, Wasmuth S, Steuhl KP, Heiligenhaus A. Matrix metalloproteinases (MMP-2 and 9) and tissue inhibitors of matrix metalloproteinases (TIMP-1 and 2) during the course of experimental necrotizing herpetic keratitis. Experimental Eye Research 2003; 77: 227-237.
155. Choudhary A, Hiscott P, Hart CA, Kaye SB, Batterbury M, Grierson I. Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes. Molecular Vision 2005; 11: 163-168.
156. Biswas PS, Banerjee K, Kim B, Kinchington PR, Rouse BT. Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis. Journal of Virology 2005; 79: 10589-10600.
157. Psarras S, Volonaki E, Skevaki CL, et al. Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. The Journal of Allergy and Clinical Immunology 2006; 117: 291-297.
158. Kuhn H, Riedel A, Eichler W, Aust G, Gessner C, Wirtz H. Influence of adenoviral vector on expression of angiogenesis regulating factors in non-small cell lung cancer cell lines. Cancer Immunology, Immunotherapy 2002; 51: 461-466.
159. Seandel M, Butler JM, Kobayashi H, et al. Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 19288-19293.
160. Kornberg LJ, Grant MB. Adenoviruses increase endothelial cell proliferation, migration, and tube formation: partial reversal by the focal adhesion kinase inhibitor, FRNK. Microvascular Research 2007; 73: 157-162.
161. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunology and Medical Microbiology 2008; 53: 287-299.
162. Mackow ER, Gavrilovskaya IN. Hantavirus regulation of endothelial cell functions. Thrombosis and Haemostasis 2009; 102: 1030-1041.
163. Wang Z, Luo F, Li L, et al. STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. European Journal of Cancer 2010; 46(16): 2996-3006.
164. Wood VH, O'Neil JD, Wei W, Stewart SE, Dawson CW, Young LS. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene 2007; 26: 4135-4147.
165. An J, Lichtenstein AK, Brent G, Rettig MB. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood 2002; 99: 649-654.
166. Tomita M, Semenza GL, Michiels C, et al. Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells. The Biochemical Journal 2007; 406: 317-323.
167. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathogens 2006; 2: e116.